BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dai C, Liang S, Sun B, Kang J. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas. Front Endocrinol (Lausanne) 2020;11:608422. [PMID: 33362722 DOI: 10.3389/fendo.2020.608422] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Suda N. Non-surgical Interventions for Pituitary Lesions. Otolaryngologic Clinics of North America 2022. [DOI: 10.1016/j.otc.2021.12.004] [Reference Citation Analysis]
2 Goichot B, Taquet MC, Baltzinger P, Baloglu S, Gravaud M, Malouf GG, Noël G, Imperiale A. Should pituitary carcinoma be treated using a NET-like approach? A case of complete remission of a metastatic malignant prolactinoma with multimodal therapy including immunotherapy. Clin Endocrinol (Oxf) 2021. [PMID: 34845727 DOI: 10.1111/cen.14645] [Reference Citation Analysis]
3 Nie D, Xue Y, Fang Q, Cheng J, Li B, Wang D, Li C, Gui S, Zhang Y, Zhao P. Immune Checkpoints: Therapeutic Targets for Pituitary Tumors. Dis Markers 2021;2021:5300381. [PMID: 34447484 DOI: 10.1155/2021/5300381] [Reference Citation Analysis]
4 Fanciulli G, Di Molfetta S, Dotto A, Florio T, Feola T, Colao A, Faggiano A; NIKE Group. Commentary: Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management. Front Endocrinol (Lausanne) 2021;12:700806. [PMID: 34220723 DOI: 10.3389/fendo.2021.700806] [Reference Citation Analysis]
5 Lamback EB, Wildemberg LE, Gadelha MR. Current opinion on the diagnosis and management of non-functioning pituitary adenomas. Expert Rev Endocrinol Metab 2021;:1-12. [PMID: 34678108 DOI: 10.1080/17446651.2021.1988851] [Reference Citation Analysis]
6 Szydełko J, Szydełko-Gorzkowicz M, Matyjaszek-Matuszek B. Neutrophil-to-Lymphocyte, Platelet-to-Lymphocyte Ratios, and Systemic Immune-Inflammation Index as Potential Biomarkers of Chronic Inflammation in Patients with Newly Diagnosed Acromegaly: A Single-Centre Study. J Clin Med 2021;10:3997. [PMID: 34501445 DOI: 10.3390/jcm10173997] [Reference Citation Analysis]
7 Ren S, Lu Q, Xiao Y, Zhang Y, Zhang L, Li B, Li M. Coexistence of Pituitary Adenoma and Primary Pituitary Lymphoma: A Case Report and Review of the Literature. Front Surg 2022;9:842830. [DOI: 10.3389/fsurg.2022.842830] [Reference Citation Analysis]
8 Ng S, Messerer M, Engelhardt J, Bruneau M, Cornelius JF, Cavallo LM, Cossu G, Froelich S, Meling TR, Paraskevopoulos D, Schroeder HWS, Tatagiba M, Zazpe I, Berhouma M, Daniel RT, Laws ER, Knosp E, Buchfelder M, Dufour H, Gaillard S, Jacquesson T, Jouanneau E. Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section. Acta Neurochir (Wien) 2021;163:3131-42. [PMID: 34365544 DOI: 10.1007/s00701-021-04953-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Nie D, Fang Q, Li B, Cheng J, Li C, Gui S, Zhang Y, Zhao P. Research advances on the immune research and prospect of immunotherapy in pituitary adenomas. World J Surg Oncol 2021;19:162. [PMID: 34090476 DOI: 10.1186/s12957-021-02272-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]